NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free EVOK Stock Alerts $0.44 -0.01 (-2.24%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.4550-Day Range$0.44▼$0.7052-Week Range$0.42▼$2.40Volume15,641 shsAverage Volume53,776 shsMarket Capitalization$3.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Evoke Pharma alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesApril 18, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93April 18, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.comApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | finance.yahoo.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 17, 2024 | globenewswire.comEvoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsApril 10, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsightApril 10, 2024 | msn.comEmpowering students: Innovative approaches to climate change educationApril 10, 2024 | finance.yahoo.comStephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy TeamApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 1, 2024 | msn.comHow a Dubai man built a $200,000 art collection in his Business Bay homeMarch 30, 2024 | msn.comThe Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-ColaMarch 30, 2024 | msn.comBrain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlertMarch 22, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 21, 2024 | marketwatch.comEvoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO GonyerMarch 21, 2024 | finance.yahoo.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerMarch 21, 2024 | globenewswire.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 18, 2024 | msn.comBig change is the only constant in eco: India IncMarch 17, 2024 | seekingalpha.comEvoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | finance.yahoo.comEvoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?March 15, 2024 | msn.comBrain gain: Hope rises with new dementia treatmentsMarch 15, 2024 | finance.yahoo.comEvoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | msn.comEVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023March 14, 2024 | msn.com‘Would have torn Modi into pieces’: DMK minister TM Anbarasan booked for remarks against PMMarch 14, 2024 | globenewswire.comEvoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comA Preview Of Evoke Pharma's EarningsMarch 13, 2024 | markets.businessinsider.comEvoke Pharma Inc Registered Shs hosts conference call for investorsSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/25/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-150.43% Pretax Margin-150.40% Return on Equity-517.99% Return on Assets-91.83% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.09 Sales & Book Value Annual Sales$5.18 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-0.57Miscellaneous Outstanding Shares8,480,000Free Float7,479,000Market Cap$3.70 million OptionableNot Optionable Beta0.22 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Matthew J. D'Onofrio MBA (Age 54)Co-Founder, CEO & Director Comp: $779.37kDr. Marilyn R. Carlson D.M.D. (Age 76)M.D., RAC., Chief Medical Officer Comp: $681.24kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsMustang BioNASDAQ:MBIOVirpax PharmaceuticalsNASDAQ:VRPXGeoVax LabsNASDAQ:GOVXPhaseBio PharmaceuticalsNASDAQ:PHASHillstream BioPharmaNASDAQ:HILSView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed in 2024? Evoke Pharma's stock was trading at $1.0503 at the beginning of 2024. Since then, EVOK shares have decreased by 58.5% and is now trading at $0.4360. View the best growth stocks for 2024 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 36,600 shares, a decrease of 31.5% from the March 31st total of 53,400 shares. Based on an average daily trading volume, of 42,500 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.5% of the company's shares are sold short. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) issued its earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter. The specialty pharmaceutical company earned $1.68 million during the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 517.99% and a negative net margin of 150.43%. When did Evoke Pharma's stock split? Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What guidance has Evoke Pharma issued on next quarter's earnings? Evoke Pharma issued an update on its FY 2024 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVOK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
